Sign In
25 Nov 2009 12:37
25 November 2009
Cyprotex PLC
("Cyprotex" or the "Company")
Director's Dealing
The Company received notification that Dr Anthony Baxter, Chief Executive Officer of the Company, acquired 120,000 ordinary shares in the Company on 25 November 2009 at a price of 3.45 pence per share. As a result of this purchase, Dr Baxter has an interest in 841,400 ordinary shares in the Company representing approximately 0.47 per cent. of the Company's total voting rights.
For further information:
|
Cyprotex PLC |
Tel: +44 (0) 1625 505 100 |
|
|
John Dootson, Chief Financial Officer |
||
|
ir@cyprotex.com |
www.cyprotex.com |
|
|
Noble & Company |
Tel: +44 (0) 20 7763 2200 |
|
|
John Llewellyn-Lloyd john.llewellyn-lloyd@noblegp.com |
||
|
Sam Reynolds |
||
|
sam.reynolds@noblegp.com |
www.noblegp.com |
|
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
|
Ben Brewerton / Ben Atwell / John Dineen |
||
|
cyprotex@fd.com |
www.fd.com |
|
CRX.L (CRX)
Follow the stocks
